This observational cohort study found that BAAS questionnaire is not a suitable tool for monitoring whether older patients with mCRPC are adherent to their antiandrogen therapy; however, pill counting was effective.
Traditionally, approaches to the management of patients with nonmetastatic CRPC following radical prostatectomy have been limited.
Men with biochemically recurrent nonmetastatic prostate cancer following radical prostatectomy have long survival times from the time of surgery without hormonal treatment, a study found.
The guideline includes strategies to identify patients with nonmetastatic cancer who may be at a higher risk for osteoporotic fractures.
Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes.
New study shows prolonged time to development of castration-resistant prostate cancer among men with absolute testosterone levels below 20 ng/dL.
In a small study, men on androgen deprivation therapy for prostate cancer lost weight and experienced improved hemoglobin A1C and lipid profiles.
Androgen deprivation therapy recipients had a significantly lower risk for autoimmune diseases overall and for Graves’ disease, uveitis, and psoriasis.
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
